Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure

Autor: Gerasimos Filippatos, João Pedro Ferreira, Anne Pernille Ofstad, Waheed Jamal, Christoph Wanner, Javed Butler, Elke Schüler, Martina Brueckmann, Investigators, Stuart J. Pocock, Milton Packer, Faiez Zannad, EMPEROR-Reduced Trial Committees, Piotr Ponikowski, Stefan D. Anker, Michael Böhm, Felix Mahfoud

Publikováno v: Journal of the American College of Cardiology
Journal of the American College of Cardiology, Elsevier, 2021, 78 (13), pp.1337-1348. ⟨10.1016/j.jacc.2021.07.049⟩

International audience; Background: Empagliflozin reduces the risk of cardiovascular death or heart failure (HF) hospitalization in patients with reduced ejection fraction. Its interplay with systolic blood pressure (SBP) is not known.Objectives: The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b96fc9228db16a615cd8317bfd0a6654
https://doi.org/10.1016/j.jacc.2021.07.049

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Autor: João Pedro Ferreira, Piotr Ponikowski, Muhammad Shahzeb Khan, Stefan D. Anker, Stuart J. Pocock, Milton Packer, Gerasimos Filippatos, Naveed Sattar, Javed Butler, Martina Brueckmann, EMPEROR-Reduced Trial Committees, Subodh Verma, James L. Januzzi, Faiez Zannad, Ola Vedin, Ileana L. Piña, Nadia Giannetti, Waheed Jamal, Barbara Peil, Cordula Zeller, Carolyn S.P. Lam, Investigators

Publikováno v: European Heart Journal
European Heart Journal, Oxford University Press (OUP), 2021, ⟨10.1093/eurheartj/ehaa1007⟩
European Heart Journal, Oxford University Press (OUP): Policy B, 2021, ⟨10.1093/eurheartj/ehaa1007⟩

Aims In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7b0881e286575eb718f813d87e95072
http://europepmc.org/articles/PMC8014525

Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

Autor: Milton Packer, Stuart J. Pocock, Subodh Verma, Dan Cotton, Faiez Zannad, Tomoko Iwata, Stefan D. Anker, Investigators, Janet Schnee, James L. Januzzi, Ola Vedin, Gerasimos Filippatos, Javed Butler, João Pedro Ferreira, Naveed Sattar, EMPEROR-Reduced Trial Committees

Publikováno v: Journal of the American College of Cardiology
Journal of the American College of Cardiology, Elsevier, 2021, 78 (13), pp.1321-1332. ⟨10.1016/j.jacc.2021.07.046⟩

International audience; Background: The relationship between the benefits of empagliflozin in heart failure with reduced ejection fraction (HFrEF) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) has not been reported.Objectives: The authors

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f10166c7ae39f6b4107e5676373ae88
https://hal.univ-lorraine.fr/hal-03357955/file/1-s2.0-S0735109721057843-main.pdf

Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial

Autor: Packer, Milton, Anker, Stefan D, Butler, Javed, Filippatos, Gerasimos, Ferreira, Joao Pedro, Pocock, Stuart J, Sattar, Naveed, Brueckmann, Martina, Jamal, Waheed, Cotton, Daniel, Iwata, Tomoko, Zannad, Faiez, EMPEROR-Reduced Trial Committees and Investigators

Background\ud Investigators have hypothesized that sodium-glucose cotransporter 2 (SGLT2) inhibitors exert diuretic effects that contribute to their ability to reduce serious heart failure events, and this action is particularly important in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::022dc02b6dc45a72c57e3c7fde8b6850
https://researchonline.lshtm.ac.uk/id/eprint/4662771/1/1-s2.0-S0735109721002023-main.pdf

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Autor: Butler, Javed, Anker, Stefan D, Filippatos, Gerasimos, Khan, Muhammad Shahzeb, Ferreira, João Pedro, Pocock, Stuart J, Giannetti, Nadia, Januzzi, James L, Piña, Ileana L, Lam, Carolyn SP, Ponikowski, Piotr, Sattar, Naveed, Verma, Subodh, Brueckmann, Martina, Jamal, Waheed, Vedin, Ola, Peil, Barbara, Zeller, Cordula, Zannad, Faiez, Packer, Milton, EMPEROR-Reduced Trial Committees and Investigators

AIMS: In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients with heart failure with r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::3105c87bb40f34d83c853efb87cf1c59
https://researchonline.lshtm.ac.uk/id/eprint/4659611/1/ehaa1007.pdf